论文部分内容阅读
目的观察眼局部应用贝伐单抗治疗角膜新生血管3个月的临床疗效。方法非随机选择7例10眼患有角膜新生血管的患者,所有患者均应用12.5g.L-1贝伐单抗滴眼液滴眼,每天2次。对所有患者行视力、裂隙灯检查和眼压测量,并观察角膜新生血管和各项指标的变化。结果12.5g.L-1贝伐单抗滴眼液滴眼治疗角膜新生血管患者第1个月内10眼患者中有7眼角膜新生血管减少。而10眼患者中有6眼可观察到角膜上皮缺失和上皮侵蚀,1眼角膜最终细线化。在治疗的第2个月可观察到更多的不良反应。结论眼局部应用贝伐单抗治疗角膜新生血管在治疗的第1个月可减轻角膜新生血管。然而,在治疗的第2个月患者会出现较多副作用。
Objective To observe the clinical effect of topical application of bevacizumab in the treatment of corneal neovascularization for 3 months. Methods Seven patients (10 eyes) with corneal neovascularization were randomly selected. All patients were treated with 12.5g.L-1 bevacizumab instillation twice daily. All patients underwent visual acuity, slit lamp examination and intraocular pressure measurement, and observed corneal neovascularization and changes in various indicators. Results Twelve corneal neovascularization were observed in 10 eyes of patients with corneal neovascularization at 12.5g.L-1 bevacizumab. In 6 out of 10 patients, corneal epithelium loss and epithelial erosion were observed, and the cornea was eventually thinned in one eye. More adverse reactions were observed during the second month of treatment. Conclusion Intraocular application of bevacizumab in the treatment of corneal neovascularization can reduce corneal neovascularization in the first month of treatment. However, patients have more side effects during the second month of treatment.